News

Genomic testing of patient leukemia cells uncovers genetic alterations that can be targeted by drug therapies in many patients.

Established in 2015 and supported by the Tobias Foundation, the prize recognizes original and promising basic hematology research as well as direct translational or clinical research related to cell therapy in hematological disorders.

Abatacept (Orencia) reduces rates of acute GVHD, boosts survival in Phase 2 multicenter trial.

Boston magazine has named a number of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center faculty members to its annual "Top Doctors" guide.

The gift will support pediatric research, holiday gifts, and virtual events for pediatric patients and their families as part of the company’s global Amazon Goes Gold campaign during Childhood Cancer Awareness Month.

U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the top pediatric cancer program in New England and #2 in the nation in its 2020-21 Best Children's Hospitals report.

A collaboration between the Finnish Cancer Registry and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center explored the utility of population-based registry data to screen childhood cancer patients for history of familial cancer. The study opened a new method for identifying high risk families that may reveal possible novel cancer predisposition genes.

The Harrington Discovery Institute and The American Society for Clinical Investigation honor Dr. Orkin for his contributions to red blood cell biology.

The report’s authors include investigators from Dana-Farber, Brigham and Women’s, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, the Broad Institute of MIT and Harvard, and Pitié-Salpêtrière hospitals in Paris, France, among others.

Daniel Bauer, MD, PhD, is a physician-scientist whose research focuses on functional genomics to dissect determinants of blood cell development and disease and develop innovative therapies.